company background image
532637 logo

Mangalam Drugs & Organics BSE:532637 Stock Report

Last Price

₹115.40

Market Cap

₹1.9b

7D

3.5%

1Y

17.1%

Updated

31 Dec, 2024

Data

Company Financials

Mangalam Drugs & Organics Limited

BSE:532637 Stock Report

Market Cap: ₹1.9b

532637 Stock Overview

Together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. More details

532637 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health3/6
Dividends0/6

Rewards

Price-To-Earnings ratio (19.4x) is below the Indian market (32.2x)

Became profitable this year

Risk Analysis

Interest payments are not well covered by earnings

Does not have a meaningful market cap (₹2B)


My Notes

Capture your thoughts, links and company narrative

Mangalam Drugs & Organics Limited Competitors

Aarey Drugs & Pharmaceuticals

BSE:524412

₹1.6b

Auro Laboratories

BSE:530233

₹1.7b

Kimia Biosciences

BSE:530313

₹2.1b

Quest Laboratories

NSEI:QUESTLAB

₹1.8b

Price History & Performance

Summary of share price highs, lows and changes for Mangalam Drugs & Organics
Historical stock prices
Current Share Price₹115.40
52 Week High₹144.65
52 Week Low₹85.16
Beta0.78
1 Month Change-5.68%
3 Month Change-8.74%
1 Year Change17.13%
3 Year Change-16.04%
5 Year Change263.46%
Change since IPO259.50%

Recent News & Updates

Recent updates

Shareholder Returns

532637IN PharmaceuticalsIN Market
7D3.5%2.0%-0.3%
1Y17.1%39.5%16.3%

Return vs Industry: 532637 underperformed the Indian Pharmaceuticals industry which returned 39.5% over the past year.

Return vs Market: 532637 matched the Indian Market which returned 16.3% over the past year.

Price Volatility

Is 532637's price volatile compared to industry and market?
532637 volatility
532637 Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.1%

Stable Share Price: 532637 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 532637's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1972432Govardhan Dhootwww.mangalamdrugs.com

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers API products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; and ortho phenoxy methane sulfonanilide, tenofovir alafenamide base, and tenofovir disoproxil base.

Mangalam Drugs & Organics Limited Fundamentals Summary

How do Mangalam Drugs & Organics's earnings and revenue compare to its market cap?
532637 fundamental statistics
Market cap₹1.87b
Earnings (TTM)₹94.03m
Revenue (TTM)₹3.55b

19.4x

P/E Ratio

0.5x

P/S Ratio

Is 532637 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
532637 income statement (TTM)
Revenue₹3.55b
Cost of Revenue₹2.12b
Gross Profit₹1.44b
Other Expenses₹1.34b
Earnings₹94.03m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 14, 2025

Earnings per share (EPS)5.94
Gross Margin40.41%
Net Profit Margin2.65%
Debt/Equity Ratio61.6%

How did 532637 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 13:58
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mangalam Drugs & Organics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vijay MadunalaFirstCall Research